New Jersey Better Educational Savings Trust maintained its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,200 shares of the medical research company’s stock at the end of the second quarter. New Jersey Better Educational Savings Trust’s holdings in Amgen were worth $723,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. TrimTabs Asset Management LLC raised its stake in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after acquiring an additional 288 shares during the period. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after acquiring an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after acquiring an additional 4 shares during the period. American Beacon Advisors Inc. purchased a new position in shares of Amgen in the 1st quarter valued at $106,000. Finally, Grove Bank & Trust raised its stake in shares of Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after acquiring an additional 341 shares during the period. 78.08% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “New Jersey Better Educational Savings Trust Maintains Stake in Amgen Inc. (AMGN)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/22/new-jersey-better-educational-savings-trust-maintains-stake-in-amgen-inc-amgn.html.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.19% of the company’s stock.

Amgen Inc. (NASDAQ AMGN) opened at 182.96 on Friday. The stock has a 50 day moving average of $185.13 and a 200 day moving average of $171.60. The firm has a market capitalization of $133.50 billion, a price-to-earnings ratio of 16.66 and a beta of 1.36. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.84 EPS. Equities research analysts anticipate that Amgen Inc. will post $12.58 earnings per share for the current year.

A number of equities analysts have recently commented on AMGN shares. Cann reissued a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $203.00 target price on shares of Amgen in a research note on Thursday, September 7th. Mizuho reissued a “buy” rating and issued a $198.00 target price (up previously from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Morgan Stanley reissued an “overweight” rating and issued a $196.00 target price (up previously from $189.00) on shares of Amgen in a research note on Friday, October 6th. Finally, Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Twelve analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $189.94.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.